HER2-Positive Breast Cancer: Latest Treatment Strategies

This session reviews the therapeutic landscape for HER2-positive breast cancer, a subtype with significant advancements in targeted therapy. Topics include HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates like trastuzumab deruxtecan. Experts will evaluate current treatment algorithms and emerging trials aiming to further improve survival and reduce relapse.

    Related Conference of HER2-Positive Breast Cancer: Latest Treatment Strategies

    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    December 08-09, 2025

    13th Euro Breast Cancer and Therapeutics

    Paris, France
    February 05-06, 2026

    11th World Conference on Breast and Cervical Cancer

    Paris, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 09-10, 2026

    4th World Congress on Oral Cancer

    Singapore City, Singapore
    June 15-16, 2026

    10th Global Meeting on Oncology and Radiology

    Paris, France
    June 22-23, 2026

    16th World Congress on Breast Cancer

    Dubai, UAE
    July 27-28, 2026

    6th World Congress on Breast Cancer

    Rome, Italy
    September 28-29, 2026

    36th Experts Meet On Cancer Research & Therapy

    Aix-en-Provence, France
    September 29-30, 2026

    5th Experts Meeting on Cancer Medicine, Radiology & Treatment

    Aix-en-Provence, France

    HER2-Positive Breast Cancer: Latest Treatment Strategies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in